VEGF TRAP FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 多发性骨髓瘤（MM）是浆细胞的恶性克隆性增殖，其特征在于单一免疫球蛋白同种型（M蛋白）的过度产生。我们的研究小组是最早提出MM潜在病理生理学统一概念的研究小组之一。该模型提出恶性浆细胞无法通过细胞凋亡进行细胞死亡。VEGF是由组织产生的刺激血管生成的分子。肿瘤产生的VEGF是血管形成所必需的，因此是肿瘤存活和生长所必需的。VEGF。VEGF Trap是VEGF信号传导的长效抑制剂，有效结合并灭活VEGF，从而阻断癌症动物模型和患有各种癌症的人类中的肿瘤血管生成和生长。本研究的目的是评价VEGF Trap在难治性或复发性多发性骨髓瘤（MM）患者中的安全性和有效性，并进行相关研究，以评价VEGF Trap治疗过程中患者组织的血管生成特性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Multiple Myeloma (MM) is a malignant clonal proliferation of plasma cells characterized by the excessive production of a single immunoglobulin protein isotype (M-protein). Our group was one of the first to propose a unified concept for the underlying pathophysiology of MM. This model proposes that malignant plasma cells fail to undergo cell death through apoptosis. VEGF is a molecule produced by tissues to stimulate angiogenesis. VEGF production by tumors is required for the vascularization, and thus, the survival and growth of tumors. VEGF. The VEGF Trap, a long-acting inhibitor of VEGF signaling, potently binds and inactivates VEGF, thus blocking tumor angiogenesis and growth in both animal models of cancer and in humans with a variety of cancers. The purpose of this study is to evaluate the safety and efficacy of VEGF Trap in patients with refractory or relapsed multiple myeloma (MM) and to perform correlative studies in order to evaluate the angiogenic properties of tissue from patients during the course of treatment with VEGF Trap.